The clinical characteristics of three subgroups of non-functioning pituitary adenomas

Abstract Full-Text HTML Download Download as PDF (Size:170KB) PP. 75-84
DOI: 10.4236/wjns.2014.41009    3,485 Downloads   5,193 Views  

ABSTRACT

Introduction: Despite the fact that non-functioning pituitary adenomas do not overproduce hormones, many will stain positive for a particular pituitary hormone, which can be used to differentiate these adenomas into subgroups. If these different sub-groups behave differently in terms of post surgical progression of disease (PSPD) rates or other clinical variables, then better treatment and prognosis could be predicted. Methods: This was a retrospective cohort study. Patients who have undergone surgery for removal of a non-functioning pituitary adenoma at Emory University Hospital served as the source for all data used in this study (n = 184). Data were collected from a database of electronic medical records (EMRs) for these patients in 2010 documenting clinical and demographic variables including treatment and PSPD. Results: Risk for PSPD did not differ by adenoma subtypes: follicle-stimulating hormone (FSH+), luteinizing hormone (LH+), or those that do not stain positive for any hormone (non-functioning, or NF?) (p = 0.971). There were two clinical characteristics statistically related to adenoma subtype: altered mental status and the anterior-posterior (AP) dimension of pre-operative adenomas. PSPD was related to several clinical characteristics, including gender, previous adenoma, post-operative residual, and follow-up time.

Cite this paper

Hull, A. , Milhollin, S. , Vena, J. and LaBorde, D. (2014) The clinical characteristics of three subgroups of non-functioning pituitary adenomas. World Journal of Neuroscience, 4, 75-84. doi: 10.4236/wjns.2014.41009.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] Alexander, J.M., et al. (1990) Clinically nonfunctioning pituitary tumors are monoclonal in origin. The Journal of Clinical Investigation, 86, 336-340.
http://dx.doi.org/10.1172/JCI114705
[2] Moreno, C.S., et al. (2005) Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses. Cancer Research, 65, 10214-10222. http://dx.doi.org/10.1158/0008-5472.CAN-05-0884
[3] Ebersold, M.J., et al., (1986) Long-term results in transsphenoidal removal of nonfunctioning pituitary adenomas. Journal of Neurosurgery, 64, 713-719.
http://dx.doi.org/10.3171/jns.1986.64.5.0713
[4] Chun, M., G.B. Masko, and S. Hetelekidis (1988) Radiotherapy in the treatment of pituitary adenomas. International Journal of Radiation Oncology *Biology* Physics, 15, 305-309.
http://dx.doi.org/10.1016/S0360-3016(98)90009-8
[5] Grigsby, P.W., et al. (1988) Prognostic factors and results of radiotherapy alone in the management of pituitary adenomas. International Journal of Radiation Oncology *Biology* Physics, 15, 1103-1110.
http://dx.doi.org/10.1016/0360-3016(88)90191-5
[6] Comtois, R., et al. (1991) The clinical and endocrine outcome to trans-sphenoidal microsurgery of nonsecreting pituitary adenomas. Cancer, 68, 860-866.
http://dx.doi.org/10.1002/1097-0142(19910815)68:4<860::AID-CNCR2820680431>3.0.CO;2-4
[7] Chandler, W.F. and A.L. Barkan (2008) Treatment of pituitary tumors: A surgical perspective. Endocrinology and Metabolism Clinics of North America, 37, 51-66, viii.
http://dx.doi.org/10.1016/j.ecl.2007.10.006
[8] Boelaert, K. and N.J. Gittoes (2001) Radiotherapy for non-functioning pituitary adenomas. European Journal of Endocrinology, 144, 569-575.
http://dx.doi.org/10.1530/eje.0.1440569
[9] Park, P., et al. (2004) The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas. Neurosurgery, 55, 100-106; discussion 106-107.
http://dx.doi.org/10.1227/01.NEU.0000126885.71242.D7
[10] Colao, A., et al. (2008) Medical therapy for clinically non-functioning pituitary adenomas. Endocrine-Related Cancer, 15, 905-915.
http://dx.doi.org/10.1677/ERC-08-0181
[11] Johnson, M.D., Woodburn, C.J. and Vance, M.L. (2003) Quality of life in patients with a pituitary adenoma. Pituitary, 6, 81-87.
http://dx.doi.org/10.1023/B:PITU.0000004798.27230.ed
[12] Dekkers, O.M., et al. (2006) Quality of life is decreased after treatment for nonfunctioning pituitary macroadenoma. The Journal of Clinical Endocrinology and Metabolism, 91, 3364-3369.
http://dx.doi.org/10.1210/jc.2006-0003
[13] Dekkers, O.M., et al. (2007) The natural course of nonfunctioning pituitary macroadenomas. European Journal of Endocrinology, 156, 217-224.
http://dx.doi.org/10.1530/eje.1.02334
[14] Dekkers, O.M., et al. (2006) Observation alone after transsphenoidal surgery for nonfunctioning pituitary macroadenoma. The Journal of Clinical Endocrinology and Metabolism, 91, 1796-1801.
http://dx.doi.org/10.1210/jc.2005-2552

  
comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.